Amada Company, Ltd. – Trademark Portfolio
Entity Type: 03
Amada Company, Ltd. holds 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 7 (Machinery) — 12 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include A, CTB, AMADA, HI-LO, and DR. ABE. The owner is based in Isehara-shi, Kanagawa.
200 Ishida
Isehara-shi, Kanagawa , JP
Showing of trademarks Trademarks
Trademark Classifications
Amada Company, Ltd.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Machines and machine tools; motors and engines; machine coupling and transmission components
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Amada Company, Ltd. have?
Amada Company, Ltd. has 14 U.S. trademarks filed with the USPTO. Of these, 6 registered, 8 cancelled.
What trademark classes does Amada Company, Ltd. file in?
Amada Company, Ltd. files trademarks across 3 Nice Classification classes. The most active classes are Class 7 (Machinery), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). Class 7 covers machines and machine tools; motors and engines; machine coupling and transmission components.
What are Amada Company, Ltd.'s most well-known trademarks?
Amada Company, Ltd.'s registered trademark portfolio includes well-known marks such as A, CTB, AMADA, HI-LO, and DR. ABE. These are among 6 currently registered trademarks in the portfolio.
What is Amada Company, Ltd.'s trademark registration success rate?
Amada Company, Ltd. has a 43% trademark registration rate, with 6 out of 14 resolved applications resulting in successful registration. Currently, 0 applications are pending review.